Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Metadata
Title
Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases
Authors
Kai M. Beeh
Jutta Beier
Publication date
01-07-2009
Publisher
Springer Healthcare Communications
Published in
Advances in Therapy / Issue 7/2009
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-009-0044-3

Other articles of this Issue 7/2009

Advances in Therapy 7/2009 Go to the issue

Erratum

Erratum to: Saxagliptin: a New DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

Review

Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension

Original Research

Therapeutic effect of 1,5-pentanediol for herpes simplex labialis: a randomized, double-blind, placebo-controlled clinical trial

Erratum

Erratum to: Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis

Review

Dyslipidemia therapy update: the importance of full lipid profile assessment

Original Research

Comparing hydrocortisone and methylprednisolone in patients with septic shock

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits